sorafenib and Aging
sorafenib has been researched along with Aging in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L | 1 |
| Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S | 1 |
| Hanai, T; Ideta, T; Imai, K; Kochi, T; Miyazaki, T; Shimizu, M; Shiraki, M; Suetsugu, A; Takai, K | 1 |
Other Studies
3 other study(ies) available for sorafenib and Aging
| Article | Year |
|---|---|
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbidity; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Tumor Burden; Venous Thrombosis | 2015 |
Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aging; Carcinoma, Hepatocellular; Demography; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Linear Models; Liver Neoplasms; Male; Multivariate Analysis; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Risk Factors; Sorafenib; Withholding Treatment | 2015 |